# Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

> **NCT04225910** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 225Ac-PSMA

## Key facts

- **NCT ID:** NCT04225910
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-21
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225910, "Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04225910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*